9939 — Kintor Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- HK$389.32m
- HK$170.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.79 | ||
| Price to Tang. Book | 1.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -164.35% | ||
| Return on Equity | -108.62% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 34.23 | n/a | n/a | 666.18 | 1,620.63 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.
Directors
- Tong Youzhi CHM (59)
- Lu Yan CFO (39)
- Ruo Xu VPR
- Jianfei Yang VPR (56)
- Liandong Ma VRD (62)
- Juping Shen DGM (51)
- Dong Xunwei OTH (49)
- Wing Han Leung SEC
- Wei Geqi NED (47)
- Yan Wang NED (32)
- Gao Weipeng NED (46)
- Xu Min NID (56)
- Liang Tong NID (57)
- Yeung Wai Yim NID (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 16th, 2018
- Public Since
- May 22nd, 2020
- No. of Employees
- 225
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 447,499,600
- Address
- No.20 Songbei Road, SUZHOU, 215123
- Web
- https://www.kintor.com.cn/
- Phone
- +86 51262639909
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 9939
Similar to 9939
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Kintor Pharmaceutical share price?
As of Today at 19:12 UTC, shares in Kintor Pharmaceutical are trading at HK$0.87. This share price information is delayed by 15 minutes.
How has the Kintor Pharmaceutical share price performed this year?
Shares in Kintor Pharmaceutical last closed at HK$0.87 and the price had moved by -84.55% over the past 365 days. In terms of relative price strength the Kintor Pharmaceutical share price has underperformed the FTSE Developed Asia Pacific Index by -83.87% over the past year.
What are the analyst and broker recommendations for Kintor Pharmaceutical?
The overall consensus recommendation for Kintor Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kintor Pharmaceutical dividend yield?
Kintor Pharmaceutical does not currently pay a dividend.
Does Kintor Pharmaceutical pay a dividend?
Kintor Pharmaceutical does not currently pay a dividend.
When does Kintor Pharmaceutical next pay dividends?
Kintor Pharmaceutical does not currently pay a dividend.
How do I buy Kintor Pharmaceutical shares?
To buy shares in Kintor Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kintor Pharmaceutical?
As of the previous close price of HK$0.87, shares in Kintor Pharmaceutical had a market capitalisation of HK$389.32m.
Where are Kintor Pharmaceutical shares listed?
Here are the trading details for Kintor Pharmaceutical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 9939
What kind of share is Kintor Pharmaceutical?
Based on an overall assessment of its quality, value and momentum Kintor Pharmaceutical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kintor Pharmaceutical share price forecast for 2024?
The analyst consensus target price for shares in Kintor Pharmaceutical is HK$14.14. That is 1525.79% above the last closing price of HK$0.87.
Analysts covering Kintor Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of -CNY2.16 for the next financial year.
What is the trend in the Kintor Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kintor Pharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -68.22%.
As of the last closing price of HK$0.87, shares in Kintor Pharmaceutical were trading -62.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kintor Pharmaceutical PE Ratio?
The Kintor Pharmaceutical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kintor Pharmaceutical?
Kintor Pharmaceutical's management team is headed by:
- Tong Youzhi - CHM
- Lu Yan - CFO
- Ruo Xu - VPR
- Jianfei Yang - VPR
- Liandong Ma - VRD
- Juping Shen - DGM
- Dong Xunwei - OTH
- Wing Han Leung - SEC
- Wei Geqi - NED
- Yan Wang - NED
- Gao Weipeng - NED
- Xu Min - NID
- Liang Tong - NID
- Yeung Wai Yim - NID